HOYA Group PENTAX Medical Cleared CE Mark for DISCOVERY™, an AI Assisted Polyp Detector
Hamburg, Germany, 9 January 2020 - PENTAX Medical, a division of the HOYA Group, announced that it has cleared CE mark for DISCOVERY™, an innovative Artificial Intelligence (AI) assisted polyp detector designed to support endoscopists in finding potential polyps during a colorectal examination.
DISCOVERY™ is the outcome of a close cooperation between PENTAX Medical research center located in Augsburg, Germany, and expert clinical partners from six of the leading medical institutions across the world. For this next generation development, a total of more than 120,000 files from approximately 300 clinical cases were used for the software training. By this, DISCOVERY™ is able to assist with the detection of potential polyps in real time.
The system is built in a flat monitor to provide a high usability as it can be used with any of PENTAX Medical video endoscopy systems to highlight potential polyps. The menu is self-explaining and uses an intuitive touchscreen interface.
"The benefits for the customers are outstanding. Our vision was to bring Artificial Intelligence into the operating room in the most user-friendly way. We wanted to give doctors the possibility to use this exciting new technology to strive for a better clinical outcome and maximize the patient care.” Mr. Wolfgang Mayer, Managing Director, R & D, PENTAX Medical Augsburg mentioned.
PENTAX Medical is committed to continuously exploit the use of Artificial Intelligence in additional medical fields. By gradually enhancing the product line up, PENTAX Medical has dedicated themselves to leverage AI for the further support of customers and patients.
Prof Timo Rath, Professor of Endoscopy and Molecular Imaging, University of Erlangen, Nuremberg, Germany mentioned, "As endoscopists one of our major tasks is to reduce the incidence of colorectal cancer. I'm very confident that the DISCOVERY™ will translate into increasing our own Adenoma Detection Rate and therewith will contribute to reduce colorectal cancer mortality".
PENTAX Medical plan to launch in the first markets in spring 2020.
About PENTAX Medical
PENTAX Medical is a division of HOYA Group. The company’s mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY.
Through providing endoscopic imaging devices and solutions to the global medical community and with its headquartered in Japan, PENTAX Medical has a worldwide focus and a strong presence with R&D, regional sales, service, and in-country facilities in multiple regions around the globe.
PENTAX Medical’s Triple Aim program strives to deliver on the commitment to support its customers and their healthcare organization’s wider objectives through a transparent partnership and by providing the highest quality solutions to help them reach their goals. Enabling customers to improve patient outcomes by offering evidenced based solutions across the continuum of care, dedicated to their needs. From screening through to therapy with full scalabilities. Ensuring values by supporting the customers to improve their efficiency and minimize their healthcare costs. Enriching patient and provider’s experience by empowering every member of the care team to achieve optimal outcomes through products, education and support.
For more about PENTAX Medical, please visit www.pentaxmedical.com
Sarah Perceval – Senior Account Manager; E: email@example.com; T: +44(0)1489 557672
PENTAX Europe GmbH:
Angela Ulmer – EMEA Marketing Manager; E: firstname.lastname@example.org; T: +49 40 561 92 - 252